Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk. (3rd April 2022)
- Record Type:
- Journal Article
- Title:
- Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk. (3rd April 2022)
- Main Title:
- Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk
- Authors:
- Sharma, Ashish
Kumar, Nilesh
Parachuri, Nikulaa
Sahyoun, Jean-Yves
Kuppermann, Baruch D
Bandello, Francesco - Abstract:
- Is Part Of:
- Expert opinion on biological therapy. Volume 22:Number 4(2022)
- Journal:
- Expert opinion on biological therapy
- Issue:
- Volume 22:Number 4(2022)
- Issue Display:
- Volume 22, Issue 4 (2022)
- Year:
- 2022
- Volume:
- 22
- Issue:
- 4
- Issue Sort Value:
- 2022-0022-0004-0000
- Page Start:
- 441
- Page End:
- 443
- Publication Date:
- 2022-04-03
- Subjects:
- Gene therapy -- Periodicals
Protein drugs -- Periodicals
Peptide drugs -- Periodicals
Immunotherapy -- Periodicals
Drug delivery systems -- Periodicals
615.5 - Journal URLs:
- http://informahealthcare.com/journal/ebt ↗
http://www.ashley-pub.com/loi/ebt ↗
http://www.tandfonline.com/toc/iebt20/current ↗
http://informahealthcare.com ↗
http://miranda.ashley-pub.com/vl=2623054/cl=18/nw=1/rpsv/journal/journal1_home.htm ↗ - DOI:
- 10.1080/14712598.2022.2028772 ↗
- Languages:
- English
- ISSNs:
- 1471-2598
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002940
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21170.xml